Back to Sectors

NEO

NEOGENOMICS INC
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseBEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseBEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseBEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseBEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseBEARISH | 60% | 5/22/2026 | dilution riskBULLISH | 40% | 5/22/2026 | management changeNEUTRAL | 30% | 5/22/2026 | capital raiseMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%
bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%
bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%
bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%
bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%
bearishMay 22

Approval of 5 million additional shares for equity incentives increases potential dilution.

dilution risk
60%
bullishMay 22

Re-election of the full board of directors signals continuity in leadership.

management change
40%
neutralMay 22

Expansion of equity pool serves as a non-cash method for funding talent acquisition.

capital raise
30%

Filing History

8-KMay 22, 2026

The 8-K filing confirms that NeoGenomics has successfully cleared several corporate governance hurdles, most notably the expansion of its equity incentive pool. While the bull case views this as a green light for talent acquisition and scaling, the bear case highlights the inherent dilution and pockets of shareholder dissatisfaction. Ultimately, the filing signals that the company has the authorized capital to pursue an aggressive growth strategy, but the market will now look for tangible operational results to justify the increased share count.